Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative.

International journal of cancer - 1 Feb 2000

Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta R A, Borrello M G, Menta E, Pierotti M A, Zunino F

Abstract excerpt

ret-derived oncogenes are frequently and specifically expressed in thyroid tumors. In contrast to the ret receptor, ret oncoproteins are characterized by ligand-independent tyrosine-kinase activity and tyrosine phosphorylation. In this study, novel synthetic arylidene 2-indolinone compounds were evaluated as inhibitors of the ret/ptc1 tyrosine kinase. Four compounds inhibited ret/ptc1 activity in immunokinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Oncogene Proteins, Fusion

Share to Precipitin Tests

Share to Protein-Tyrosine Kinases

Share to Thyroid Neoplasms

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 10652431

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative.PMID 10652431Read ↗

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).Semantic proximity Read ↗

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.Semantic proximity Read ↗

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Semantic proximity Read ↗

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.Semantic proximity Read ↗

Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.Semantic proximity Read ↗

BAY 43-9006 inhibition of oncogenic RET mutants.Semantic proximity Read ↗

Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Semantic proximity Read ↗

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.Semantic proximity Read ↗

Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.Semantic proximity Read ↗

Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene.Semantic proximity Read ↗

Melatonin‐induced inhibition of proliferation and G<sub>1</sub>/S cell cycle transition delay of human choriocarcinoma JAr cells: Possible involvement of MT<sub>2</sub> (MEL<sub>1B</sub>) receptorSemantic proximity Read ↗

Structure and chemical inhibition of the RET tyrosine kinase domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.